CJC-1295 vs Ipamorelin vs MK-677: GH Peptides Compared

Growth hormone (GH) optimization is one of the most active areas of peptide research. Three compounds dominate the landscape: CJC-1295, a GHRH analog; Ipamorelin, a selective GHRP; and MK-677 (Ibutamoren), a non-peptide GH secretagogue. Each operates through a distinct mechanism, and understanding these differences is essential for designing effective research protocols.

CJC-1295 (with DAC)

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH). The “DAC” (Drug Affinity Complex) modification extends its half-life from minutes to approximately 6–8 days by binding to serum albumin. This produces sustained, elevated GH levels rather than acute pulsatile release.

• •Mechanism: Stimulates the GHRH receptor on pituitary somatotrophs
• •Half-life: ~6–8 days (with DAC)
• •GH release pattern: Sustained elevation

Ipamorelin

Ipamorelin is a selective growth hormone-releasing peptide (GHRP) that acts on the ghrelin receptor (GHS-R1a). Unlike other GHRPs such as GHRP-6 or GHRP-2, Ipamorelin is highly selective — it stimulates GH release without significantly affecting cortisol, prolactin, or appetite.

• •Mechanism: Activates ghrelin receptor (GHS-R1a) selectively
• •Half-life: ~2 hours
• •GH release pattern: Acute, pulsatile

MK-677 (Ibutamoren)

MK-677 is technically not a peptide — it is a non-peptide, orally active GH secretagogue that mimics ghrelin. It also acts on the GHS-R1a receptor but has a much longer half-life, producing sustained GH and IGF-1 elevation over 24 hours from a single oral dose.

• •Mechanism: Non-peptide ghrelin mimetic (GHS-R1a agonist)
• •Half-life: ~24 hours (oral bioavailability)
• •GH release pattern: Sustained elevation with preserved pulsatility

Synergy: CJC-1295 + Ipamorelin

One of the most researched combinations in GH peptide science is CJC-1295 paired with Ipamorelin. Because they act on different receptors (GHRH-R vs GHS-R1a), they produce a synergistic amplification of GH release that is greater than either compound alone. This dual-pathway approach more closely mimics physiological GH regulation and is widely studied in preclinical models.

Conclusion

Each of these compounds offers a unique approach to GH optimization in research settings. CJC-1295 provides sustained GHRH stimulation, Ipamorelin offers selective pulsatile release, and MK-677 delivers oral convenience with prolonged activity. The choice — or combination — depends on the specific research objectives and protocol design.